SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:gup.ub.gu.se/218397"
 

Search: onr:"swepub:oai:gup.ub.gu.se/218397" > Long-Term Outcome a...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Bengtsson, Daniel,1975-Linköpings universitet,Avdelningen för kirurgi, ortopedi och onkologi,Medicinska fakulteten (author)

Long-Term Outcome and MGMT as a Predictive Marker in 24 Patients With Atypical Pituitary Adenomas and Pituitary Carcinomas Given Treatment With Temozolomide

  • Article/chapterEnglish2015

Publisher, publication year, extent ...

  • The Endocrine Society,2015

Numbers

  • LIBRIS-ID:oai:gup.ub.gu.se/218397
  • https://gup.ub.gu.se/publication/218397URI
  • https://doi.org/10.1210/jc.2014-4350DOI
  • https://lup.lub.lu.se/record/5145580URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:131177069URI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-174710URI

Supplementary language notes

  • Language:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Funding agencies: This work was supported by grants from Lund University, and the Arvid Nilsson Fund.
  • Context/Objective: Locally aggressive pituitary tumors (LAPT) and pituitary carcinomas respond poorly to conventional therapy and cytotoxic drugs. Temozolomide (TMZ) is an oral alkylating drug with good tolerability, approved for treatment of malignant gliomas. The experience of its use in pituitary tumors is limited. Design and Setting: We report on 24 patients with aggressive pituitary tumors (16 LAPTs, 8 carcinomas) treated with TMZ for a median of 6 months (range 1-23). Follow-up ranged from 4 to 91 months with a median of 32.5 months. 19/24 tumors were hormone secreting (PRL 9, ACTH 4, GH 4, GH/PRL 2). Ki-67 was 2-50% in LAPTs, and 5-80% in carcinomas. Main Outcome: Response to TMZ and the association with tumor expression of O6-methylguanine DNA methyltransferase (MGMT), MLH1, MSH2, and MSH6, examined by immunohistochemistry. Results: Complete tumor regression occurred in two carcinomas and persisted at follow-up after 48 and 91 months, respectively. Partial regress of tumor mass ranging from 35% to 80% occurred in 5 LAPTs and 2 carcinomas. Another patient with LAPT had a 71% decrease in prolactin levels without change in tumor volume. Three LAPTs could not be evaluated. Median MGMT staining was 9% (5-20%) in responders vs 93% (50-100%) in nonresponders. Loss of MSH2 and MSH 6 was observed in a single patient who had a rapid development of resistance to TMZ. Conclusions: This study shows that TMZ is a valuable treatment option for patients with uncontrolled pituitary tumors. The data suggest that tumoral MGMT staining below 50% is associated with a high likelihood of treatment response.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Schroder, H. D.Department of Pathology (H.D.S.) Odense, Denmark (author)
  • Andersen, M.Department of Endocrinology (M.A.), Odense University Hospital, University of Southern Denmark, Odense, Denmark (author)
  • Maiter, D.Department of Endocrinology and Nutrition (D.M.), Cliniques Universitaires St-Luc, Université Catholique de Louvain, Brussels, Belgium (author)
  • Berinder, K.Karolinska Institutet,Department of Endocrinology, Metabolism and Diabetology (K.B., C.H., M.P.), Karolinska University Hospital, Stockholm, Sweden (author)
  • Rasmussen, U. F.Department of Medical Endocrinology and Metabolism (U.F.R, Å.K.R), Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark (author)
  • Rasmussen, A. K.Department of Medical Endocrinology and Metabolism (U.F.R, Å.K.R), Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark (author)
  • Johannsson, Gudmundur,1960Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för invärtesmedicin och klinisk nutrition,Institute of Medicine, Department of Internal Medicine and Clinical Nutrition,Department of Endocrinology (G.J., O.R.), Institute of Medicine, Sahlgrenska Academy, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden(Swepub:gu)xjgudn (author)
  • Hoybye, C.Karolinska Institutet,Department of Endocrinology, Metabolism and Diabetology (K.B., C.H., M.P.), Karolinska University Hospital, Stockholm, Sweden (author)
  • van der Lely, A. J.Department of Medicine, Division of Endocrinology (A.J.v.d.L.), Erasmus University MC, Rotterdam, The Netherlands (author)
  • Petersson, M.Karolinska Institutet,Department of Endocrinology, Metabolism and Diabetology (K.B., C.H., M.P.), Karolinska University Hospital, Stockholm, Sweden (author)
  • Ragnarsson, Oskar,1971Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för invärtesmedicin och klinisk nutrition,Institute of Medicine, Department of Internal Medicine and Clinical Nutrition,Department of Endocrinology (G.J., O.R.), Institute of Medicine, Sahlgrenska Academy, University of Gothenburg; Sahlgrenska University Hospital, Gothenburg, Sweden(Swepub:gu)xragos (author)
  • Burman, PiaLund University,Lunds universitet,Genomik, diabetes och endokrinologi,Forskargrupper vid Lunds universitet,Genomics, Diabetes and Endocrinology,Lund University Research Groups,Department of Endocrinology (D.B., P.B.), Skane University Hospital, Malmö, Sweden(Swepub:lu)med-bap (author)
  • Linköpings universitetAvdelningen för kirurgi, ortopedi och onkologi (creator_code:org_t)

Related titles

  • In:Journal of Clinical Endocrinology & Metabolism: The Endocrine Society100:4, s. 1689-16980021-972X1945-7197

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view